ReviewJournal of drug assessment2019
Epidemiology of atopic dermatitis in Europe.
Review in Journal of drug assessment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Is Atopic Dermatitis Associated with Systemic Metabolic Disturbances? A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Vitamin D Supplementation for Treating Atopic Dermatitis in Children and Adults: A Systematic Review and Meta-Analysis.Nutrients · 2024Pooled it
- Integrative transcriptome-wide analysis of atopic dermatitis for drug repositioning.Communications biology · 2022Pooled it
- Are behavioral interventions a better choice for atopic dermatitis patients? A meta-analysis of 6 randomized controlled trials.Anais brasileiros de dermatologiaPooled it
- Current research landscape and future prospects of in silico modeling approaches for atopic dermatitis.JID innovations : skin science from molecules to population health · 2026Review
- AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis.Dermatology and therapy · 2026Article
- Treatment Patterns and Burden of Atopic Dermatitis in Adults in the United Arabic Emirates, Saudi Arabia, Kuwait, Qatar and Turkey: A Real-World Study.Dermatology and therapy · 2026Article
- Evaluation of sulfobutylether-β-cyclodextrin complex loaded dissolving microneedles-mediated delivery of fluticasone propionate for atopic dermatitis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Maternal Anxiety and Psychosocial Burden in Childhood Atopic Dermatitis: A Comparative Study.Actas espanolas de psiquiatria · 2026Article
- Atopic Dermatitis in Denmark: Regional Variation.Acta dermato-venereologica · 2026Article
- A skin isolate ofFrontiers in immunology · 2026Article
- Trends and projections of dermatitis burden (1990-2040): a 2021 global burden of disease analysis.Frontiers in medicine · 2026Article
- A Multicenter Cross-Sectional Study on Clinical Characteristics and Disease Burden of 1010 Patients with Moderate to Severe Atopic Dermatitis in Chinese Tertiary Hospitals.Clinical, cosmetic and investigational dermatology · 2026Article
- Burden of Disease and Treatment Patterns in Adults with Atopic Dermatitis from the Baltic Region: Real-World Data from the ESSENTIAL AD Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2025Observational
- Hereditary angioedema: A national investigation of associated comorbidities and surgical procedures.The World Allergy Organization journal · 2025Article
- Elevated Serum Levels of miRNA-155 in Children with Atopic Dermatitis: A Potential Biomarker of Disease.International journal of molecular sciences · 2025Article
- Early-Life Environmental Determinants of Allergic Conditions in Children with Atopic Heredity: A Single Center Cross-Sectional Study from Bulgaria.Medical sciences (Basel, Switzerland) · 2025Article
- Biological mechanisms and therapeutic prospects of interleukin-33 in pathogenesis and treatment of allergic disease.Journal of inflammation (London, England) · 2025Review
- Characterizing Patients and Treatment Patterns in Moderate-to-severe Atopic Dermatitis in Finland: A Population-based Study Using National Health Data.Acta dermato-venereologica · 2025Observational
- Restorative effects of camellia oil on the skin-barrier function in a model of DNCB-induced atopic dermatitis.European journal of histochemistry : EJH · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a chronic inflammatory disease persisting predominantly in the pediatric population. Its development is most presumably multifactorial and a derivative of interplay between genetic, immunologic, and environmental causes. To the authors' knowledge, no multinational and systematic database of AD prevalence is established and maintained for Europe. Thus, epidemiologic data originating from the multinational studies was compiled to draw a picture of AD in both pediatric and adult populations in Europe. The outcomes of this exercise support the general observation that AD prevalence follows the latitudinal pattern with higher prevalence values in northern Europe and decreases progressively towards southern Europe. Noteworthy, the data shows significant differences on the country-level, with higher prevalence in municipal areas than rural. Finally, and unsurprisingly, the collected data reinforces the observation of AD prevalence being highest in pediatric populations in contrast to adults. Herein, data presented was additionally supplemented with the information on current standing on AD etiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.